ClinicalTrials.gg
CompletedNCT01226485Updated Sep 13, 2019Results posted

A Study in Advanced Cancer

A Phase 1 interventional study of Taladegib in Advanced Cancer, sponsored by Eli Lilly and Company. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.

Read the detailed description

Participants may include those who have previously received treatment with another hedgehog smoothened (Hh/Smo) inhibitor (excluding LY2940680).

02

Conditions studied

  • Advanced Cancer

Keywords

  • Cancer
  • Terminal
  • Solid Tumor
  • End Stage
  • Metastatic
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 84 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or . The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy.
  • Have the presence of measurable or nonmeasurable disease
  • Have adequate organ function, including:

    • Hematologic: (ANC) greater than or equal to 1.5 x 109/L, greater than or equal to 100 x 109/L, and greater than or equal to 9 g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin until 5 days after the erythrocyte transfusion.
    • Hepatic: less than or equal to 1.5 times (ULN), , and aspartate transferase (AST) less than or equal to 2.0 times ULN. If the liver has tumor involvement AST and ALT equaling less than or equal to 5 times ULN are acceptable.
    • Renal: Serum creatinine less than or equal to 1.5 times ULN.
  • Have a performance status of less than or equal to 1 on the (ECOG) scale
  • Have discontinued previous treatments for cancer and recovered from the acute effects of therapy (for example, at least 42 days for mitomycin-C or nitrosoureas, 28 days for other chemotherapy and biologics. At the discretion of the investigator, hormone prostate cancer patients who are stable on gonadotropin-releasing hormone (GnRH) agonist therapy and breast cancer patients who are stable on antiestrogen therapy (for example, an aromatase inhibitor) may continue treatment

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within 21 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication.
  • Have serious preexisting medical conditions
  • Have symptomatic central nervous system (CNS) (with the exception of medulloblastoma) or (screening not required). Patients with treated are eligible for this study if they are not currently receiving and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 60 days.
  • Have known current hematologic malignancies or acute or chronic leukemia
  • Have a known active fungal, bacterial, and/or known viral infection including human immunodeficiency () or viral (A, B, or C) hepatitis (screening is not required)
  • Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
  • Have of >500 msec on screening
  • Patients who have previously received treatment with LY2940680
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Taladegib

    Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle. Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle. Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle. Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors. Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC).

    Drug: Taladegib

Interventions

  • Administered IV

    Also known as: LY2940680

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose: Maximum Tolerated Dose

    Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which was determined by Dose-limiting toxicity (DLT). For the purpose of this study, the MTD was defined as the highest tested dose that had \<33% probability of causing a DLT in Cycle 1 of Part A.

    Time frame: Time to First Dose to the End of Cycle 1 of Part A (Up To 28 Days)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])

    Pharmacokinetics (PK): 1.Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC\[0-∞\])

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  2. PK: Maximum Observed Drug Concentration (Cmax)

    PK: Maximum Observed Drug Concentration (Cmax)

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  3. PK: Time of Maximal Concentration (Tmax)

    PK: Time of Maximal Concentration (Tmax)

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  4. PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of LSN3185556

    PK: Area Under the Plasma Concentration-time Curve from time Zero to 24 Hours (AUC\[0-24\]) of LSN3185556

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  5. PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556

    PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  6. PK: Time of Maximal Concentration (Tmax) of LSN3185556

    PK: Time of Maximal Concentration (Tmax)

    Time frame: Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h

  7. Number of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR])

    Clinical Benefit Rate is complete response (CR) + partial response (PR) + stable disease (SD) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is a ≥20% increase in the sum of diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 millimeter (mm), the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions.

    Time frame: Baseline to Disease Progression or Death Due to Any Cause (Up To 32 Months)

  8. Part C and D: Progression Free Survival (PFS)

    For each participant in Part C and D who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, PFS was censored at the date of last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

    Time frame: Baseline to Progressive Disease or Death from Any Cause (Up To 32 Months)

07

Results

Posted Sep 13, 2019
Limitations and caveats
Part B of the study was not implemented as the estimated half-life was considered long enough for QD dosing.

Participant flow

Participant flow — Overall Study
MilestonePart A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart D
Started363671940
Received at least one dose of drug363671940
Completed363671940
Not completed0000000

Outcome measures

PrimaryRecommended Phase 2 Dose: Maximum Tolerated Dose

Recommended Phase 2 dose was determined by maximum tolerated dose (MTD), which was determined by Dose-limiting toxicity (DLT). For the purpose of this study, the MTD was defined as the highest tested dose that had \<33% probability of causing a DLT in Cycle 1 of Part A.

Time frame:
Time to First Dose to the End of Cycle 1 of Part A (Up To 28 Days)
Reported as:
Number · milligrams (mg)
Recommended Phase 2 Dose: Maximum Tolerated Dose
milligrams (mg)All Part A Participants
Recommended Phase 2 Dose: Maximum Tolerated Dose400
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])

Pharmacokinetics (PK): 1.Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC\[0-∞\])

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Geometric mean · nanogram*hour/milliliter (μg*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
nanogram*hour/milliliter (μg*h/mL)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 1NA ± NA8.70 ± 101NA ± NA53.7 ± 99.196.2 ± 74.8
Cycle 1, Day 15NA ± NA12.4 ± 113NA ± NA93.8 ± 103NA ± NA
SecondaryPK: Maximum Observed Drug Concentration (Cmax)

PK: Maximum Observed Drug Concentration (Cmax)

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
PK: Maximum Observed Drug Concentration (Cmax)
microgram per milliliter (μg/mL)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 1NA ± NA0.45 ± 59.871.29 ± NA2.07 ± 66.393.28 ± 34.36
Cycle 1, Day 15NA ± NA0.71 ± 71.67NA ± NA3.62 ± 59.00NA ± NA
SecondaryPK: Time of Maximal Concentration (Tmax)

PK: Time of Maximal Concentration (Tmax)

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Median · hour (h)
PK: Time of Maximal Concentration (Tmax)
hour (h)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 12.03 (2.00 to 2.22)3.92 (2.00 to 4.00)1.22 (0.75 to 4.00)2.00 (0.02 to 24.17)3.82 (1 to 6)
Cycle 1,Day 152.0 (1.00 to 4.05)4.10 (3.78 to 7.80)1.00 (0.92 to 1.88)2.00 (0.50 to 10.00)4.08 (0.88 to 8.00)
SecondaryPK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of LSN3185556

PK: Area Under the Plasma Concentration-time Curve from time Zero to 24 Hours (AUC\[0-24\]) of LSN3185556

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Geometric mean · microgram*hour/milliliter (μg*h/mL)
PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of LSN3185556
microgram*hour/milliliter (μg*h/mL)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 1NA ± NA7.91 ± 50.1NA ± NA36.6 ± 70.167.4 ± 67.7
Cycle 1, Day 15NA ± NA22.9 ± 67.6NA ± NA121 ± 81.0NA ± NA
SecondaryPK: Maximum Observed Drug Concentration (Cmax) of LSN3185556

PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
PK: Maximum Observed Drug Concentration (Cmax) of LSN3185556
microgram per milliliter (μg/mL)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 1NA ± NA0.51 ± 37.28NA ± NA2.27 ± 62.824.18 ± 73.72
Cycle 1, Day 15NA ± NA1.53 ± 60.18NA ± NA7.18 ± 72.20NA ± NA
SecondaryPK: Time of Maximal Concentration (Tmax) of LSN3185556

PK: Time of Maximal Concentration (Tmax)

Time frame:
Cycle 1, Day 1: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 hour(h), Day 15: Predose, 0.5, 1, 2, 4, 6, 8, 10,11, 12 h
Reported as:
Median · hour (h)
PK: Time of Maximal Concentration (Tmax) of LSN3185556
hour (h)50 mg Taladegib100 mg Taladegib200 mg Taladegib400 mg Taladegib600 mg Taladegib
Cycle 1, Day 124.25 (8.00 to 24.48)16.81 (6.12 to 24.43)6.00 (2.00 to 24.08)22.67 (1.13 to 25.17)24.00 (7.98 to 24.87)
Cycle 1,Day 158.00 (4.00 to 9.97)8.99 (3.78 to 10.00)8.00 (8.00 to 24.65)1.74 (0.00 to 24.92)8.00 (5.82 to 10.17)
SecondaryNumber of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR])

Clinical Benefit Rate is complete response (CR) + partial response (PR) + stable disease (SD) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD is a ≥20% increase in the sum of diameter of the target lesions taking as reference the smallest sum on study and an absolute increase in the sum diameter of ≥5 millimeter (mm), the appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions.

Time frame:
Baseline to Disease Progression or Death Due to Any Cause (Up To 32 Months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR])
ParticipantsPart A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart D
Number of Participants With Clinical Benefit Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR])21212437
SecondaryPart C and D: Progression Free Survival (PFS)

For each participant in Part C and D who is not known to have died or to have had a progression of disease as of the data inclusion cut-off date, PFS was censored at the date of last objective progression-free disease assessment prior to the date of any subsequent systemic anticancer therapy. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. PD is ≥20% increase in sum of longest diameter of target lesions and/or a new lesion.

Time frame:
Baseline to Progressive Disease or Death from Any Cause (Up To 32 Months)
Reported as:
Median · months
Part C and D: Progression Free Survival (PFS)
monthsPart CPart D
Part C and D: Progression Free Survival (PFS)1.74 (0.95 to 1.87)9.07 (7.36 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1—0/3 (0%)3/3 (100%)
Part A: Cohort 2—3/6 (50%)6/6 (100%)
Part A: Cohort 3—0/3 (0%)3/3 (100%)
Part A: Cohort 4—3/6 (50%)6/6 (100%)
Part A: Cohort 5—1/7 (14.3%)7/7 (100%)
Part C—4/19 (21.1%)19/19 (100%)
Part D—10/40 (25%)40/40 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPart A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart D
NauseaGastrointestinal disorders0/30/60/32/61/70/191/40
Abdominal painGastrointestinal disorders0/31/60/30/60/70/190/40
Gastrointestinal haemorrhageGastrointestinal disorders0/30/60/31/60/70/190/40
VomitingGastrointestinal disorders0/30/60/31/61/70/190/40
HyponatraemiaMetabolism and nutrition disorders0/31/60/30/60/70/190/40
Pleural effusionRespiratory, thoracic and mediastinal disorders0/31/60/30/60/71/190/40
PneumoniaInfections and infestations0/30/60/30/60/72/190/40
DeathGeneral disorders0/30/60/30/60/71/190/40
ArthralgiaMusculoskeletal and connective tissue disorders0/30/60/30/60/71/190/40
AnaemiaBlood and lymphatic system disorders0/30/60/30/60/70/191/40
Most frequent other events
Showing 10 of 154
Most frequent other events
EventPart A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart D
DiarrhoeaGastrointestinal disorders3/33/61/31/61/73/1913/40
FatigueGeneral disorders3/31/62/34/64/79/1924/40
VomitingGastrointestinal disorders1/32/61/35/63/77/1916/40
NauseaGastrointestinal disorders1/33/62/32/64/78/1924/40
Decreased appetiteMetabolism and nutrition disorders1/31/62/32/63/710/1917/40
Muscle spasmsMusculoskeletal and connective tissue disorders2/32/62/30/61/76/1923/40
DysgeusiaNervous system disorders2/33/62/31/64/78/1923/40
AlopeciaSkin and subcutaneous tissue disorders2/31/62/30/61/74/1921/40
RashSkin and subcutaneous tissue disorders2/30/60/30/60/72/192/40
Weight decreasedInvestigations0/30/60/30/60/75/1921/40

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Part A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart DTotal
Mean60.3 ± 14.5757.2 ± 14.1867.3 ± 7.3760.7 ± 14.0565.6 ± 11.3462.5 ± 10.5964.0 ± 12.4763.1 ± 11.92
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart DTotal
Female121326823
Male24235133261
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart DTotal
Hispanic or Latino00100124
Not Hispanic or Latino36267183880
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart DTotal
American Indian or Alaska Native00000022
Asian00000000
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000112
White36367183679
More than one race00000000
Unknown or Not Reported00000011
Region of Enrollment
Region of Enrollment(Participants)Part A: Cohort 1Part A: Cohort 2Part A: Cohort 3Part A: Cohort 4Part A: Cohort 5Part CPart DTotal
United States36367194084
08

Study locations

12 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scottsdale, Arizona 85260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Redwood City, California 94063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aurora, Colorado 80045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33908, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89169, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10065, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Worth, Texas 76177, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tyler, Texas 75702, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2015 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2010
First posted
Oct 22, 2010
Start
Sep 2010
Primary completionActual
Jan 2015
CompletionActual
Oct 2017
Results first posted
Sep 13, 2019
Last update
Sep 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01226485
Responsible party
Sponsor
First posted
Oct 22, 2010
Start date
Sep 2010
Primary completion
Jan 2015
Completion
Oct 2017
Results posted
Sep 13, 2019
Last update
Sep 13, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion